/
Avenue Therapeutics, Inc. ( Avenue or the Company ) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. Our current product candidates are ATX-04, a selective 2-adrenergic agonist for Pompe disease, intravenous tramadol ( IV tramadol ), a schedule IV opioid for the treatment of post-operative acute pain an…
$0.55
+$0.03 (+5.77%)
Price from 41 days ago
The business is unprofitable at the operating level (-219.59% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$1M
Net Income (TTM)
-$2M
▲ +75.0% YoY
Op. Margin
-219.59%
ROIC
-56.16%
▲ +301.9pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$1M
▲ +79.7% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$2M
Continue Research